我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
22
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1984
进行中（未招募）
3
13.6%
已完成
14
63.6%
招募中
1
4.5%
暂无批准数据
- The FDA approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor ALL, marking a significant advancement in CAR T-cell therapy. - A pivotal clinical trial revealed transformative findings poised to change the standard of care for children with acute lymphoblastic leukemia (ALL), marking a milestone in pediatric oncology. - Pfizer's BESPONSA received FDA approval for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell ALL, expanding treatment options for this population.
